Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
14 nov. 2018 06h30 HE
|
Novan, Inc.
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
Novan Announces Corporate Update Conference Call and Webcast
12 nov. 2018 08h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, November 14, at...
Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
01 nov. 2018 08h05 HE
|
Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
Novan Creates Dedicated Women’s Health Business Unit
25 oct. 2018 07h05 HE
|
Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation
16 oct. 2018 08h05 HE
|
Novan, Inc.
External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidatesExtension of...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
08 oct. 2018 08h00 HE
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
01 oct. 2018 08h05 HE
|
Novan, Inc.
Trial enrollment completed meaningfully ahead of scheduleTop line results targeted to be communicated no later than mid-NovemberFavorable and consistent safety profile of SB206 enabled escalation to...
Novan Receives FDA Guidance for SB204 and Acne Indication
24 sept. 2018 16h15 HE
|
Novan, Inc.
Written minutes received from Type C meeting with FDAModerate-to-severe patient pathway re-affirmedAdditional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24,...
Novan Announces Promising Clinical Results with SB414
20 août 2018 06h30 HE
|
Novan, Inc.
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract
08 août 2018 08h25 HE
|
Novan, Inc.
Company provides a comprehensive business update via its second quarter 2018 Form 10-Q filingNew incentive plan is aligned with the achievement of two specific stockholder value targets and is...